- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07687459
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).
In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
- Имя: Qinhan Chen
- Номер телефона: +86 021-50831718
- Электронная почта: Insilico-Clinicaltrial@insilico.ai
Места учебы
-
-
Anhui
-
Hefei, Anhui, Китай
- Еще не набирают
- Anhui Provincial Hospital
-
Hefei, Anhui, Китай
- Еще не набирают
- Anhui Chest Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай
- Рекрутинг
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, Китай
- Рекрутинг
- Beijing Friendship hospital, Capital Medical University
-
Beijing, Beijing Municipality, Китай
- Еще не набирают
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, Китай
- Еще не набирают
- Fuzhou University Affiliated Provincial Hospital
-
Xiamen, Fujian, Китай
- Рекрутинг
- The Second Affiliated Hospital of Xiamen Medical College
-
-
Guangdong
-
Guangzhou, Guangdong, Китай
- Рекрутинг
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Guangdong, Китай
- Еще не набирают
- Nanfang Hospital, Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, Китай
- Еще не набирают
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hainan
-
Haikou, Hainan, Китай
- Рекрутинг
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, Китай
- Еще не набирают
- The Second Hospital of Hebei Medical University
-
Shijiazhuang, Hebei, Китай
- Еще не набирают
- Hebei Medical University Third Hospital
-
-
Henan
-
Anyang, Henan, Китай
- Рекрутинг
- The People's Hospital of Anyang City
-
Nanyang, Henan, Китай
- Рекрутинг
- Nanyang First People's Hospital
-
Zhengzhou, Henan, Китай
- Еще не набирают
- Henan Provincial People's Hospital
-
Zhengzhou, Henan, Китай
- Еще не набирают
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Китай
- Еще не набирают
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, Китай
- Еще не набирают
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Yichang, Hubei, Китай
- Еще не набирают
- Yichang Central People's Hospital
-
-
Hunan
-
Changsha, Hunan, Китай
- Еще не набирают
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, Китай
- Еще не набирают
- The Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, Китай
- Еще не набирают
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай
- Рекрутинг
- Nanjing Drum Tower Hospital
-
Xuzhou, Jiangsu, Китай
- Еще не набирают
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай
- Еще не набирают
- Jiangxi Provincial People' Hospital
-
-
Jilin
-
Changchun, Jilin, Китай
- Еще не набирают
- The Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, Китай
- Еще не набирают
- Shengjing Hospital of China Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, Китай
- Рекрутинг
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an, Shaanxi, Китай
- Рекрутинг
- The First Affiliated Hospital of Xi'an Medical College
-
-
Shandong
-
Jinan, Shandong, Китай
- Еще не набирают
- Qilu Hospital of Shandong University
-
Jinan, Shandong, Китай
- Еще не набирают
- Introduction of the First Affiliated Hospital of Shandong First Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай
- Рекрутинг
- Shanghai Pulmonary Hospital Affiliated to Tongji University
-
-
Shanxi
-
Taiyuan, Shanxi, Китай
- Еще не набирают
- Shanxi Bethune Hospital
-
Yuncheng, Shanxi, Китай
- Еще не набирают
- Yuncheng Central Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Китай
- Еще не набирают
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, Китай
- Еще не набирают
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Китай
- Еще не набирают
- Tianjin Medical University General Hospital
-
Tianjin, Tianjin Municipality, Китай
- Еще не набирают
- Tianjin Chest Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, Китай
- Еще не набирают
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, Китай
- Еще не набирают
- The First People Hospital of Yunnan Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, Китай
- Еще не набирают
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Китай
- Рекрутинг
- Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
-
Jiaxing, Zhejiang, Китай
- Еще не набирают
- The First Hospital of Jiaxing
-
Ningbo, Zhejiang, Китай
- Еще не набирают
- Ningbo Medical Center Lihuili Hospital
-
Ningbo, Zhejiang, Китай
- Еще не набирают
- The First Affiliated Hospital of Ningbo University
-
Wenzhou, Zhejiang, Китай
- Еще не набирают
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
- Patients aged ≥40 years at time of signing the ICF.
- Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
- UIP or probable UIP with fibrosis extent >10% at HRCT.
Meet all the following criteria during the screening period:
- FVC ≥45% predicted of normal
- FEV1/FVC ≥0.7
- DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
Background antifibrotic therapies are allowed, patients may be either:
- on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
- not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
- Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
- Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.
Exclusion criteria:
- Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
- Previous participation in a clinical study with rentosertib (active or placebo).
- Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
- Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
- Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
- Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
- Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
- Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
- Patients with Gilbert's disease
- Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
- Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
- Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
- Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
- Patient with a history of lung volume reduction surgery or lung transplant.
- Current smoker and/or cotinine (smoking) test positive.
- History of drug abuse, drug use, or alcohol abuse within the past 3 months.
- Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
- Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
- Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
- Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study
- Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
- Medications associated with substantial risk for prolongation of corrected QT interval.
- Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
- Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
- Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
- Any condition that would interfere with the interpretation of study assessments or impair study participation.
- Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
|
Dosage form: Tablets; Frequency of administration: Orally QD.
Other Names: Rentosertib
|
|
Плацебо Компаратор: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
|
Лекарственная форма: Таблетка; Частота приема: Перорально 1 раз в день.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Временное ограничение: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
time to first occurrence of any disease progression
Временное ограничение: up to 52 weeks
|
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
|
up to 52 weeks
|
|
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Временное ограничение: week 52
|
week 52
|
|
|
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Временное ограничение: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Временное ограничение: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Временное ограничение: Weeks 0, 52
|
Weeks 0, 52
|
Другие показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Временное ограничение: up to 56 weeks
|
up to 56 weeks
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Временное ограничение: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Временное ограничение: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Временное ограничение: weeks 0, 12 ,26, and 52
|
weeks 0, 12 ,26, and 52
|
|
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Временное ограничение: weeks 0, 52
|
weeks 0, 52
|
|
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Временное ограничение: weeks 0, 52
|
weeks 0, 52
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- INS018-055-301
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .